PE20100808A1 - Anticuerpos que reconocen sulfatidos y proteoglicanos sulfatados - Google Patents
Anticuerpos que reconocen sulfatidos y proteoglicanos sulfatadosInfo
- Publication number
- PE20100808A1 PE20100808A1 PE2010000230A PE2010000230A PE20100808A1 PE 20100808 A1 PE20100808 A1 PE 20100808A1 PE 2010000230 A PE2010000230 A PE 2010000230A PE 2010000230 A PE2010000230 A PE 2010000230A PE 20100808 A1 PE20100808 A1 PE 20100808A1
- Authority
- PE
- Peru
- Prior art keywords
- sulfated
- antibody
- proteoglycans
- antibodies
- recognize
- Prior art date
Links
- 102000016611 Proteoglycans Human genes 0.000 title abstract 2
- 108010067787 Proteoglycans Proteins 0.000 title abstract 2
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 230000003143 atherosclerotic effect Effects 0.000 abstract 1
- 230000006378 damage Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/323—Arteriosclerosis, Stenosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Cardiology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Vascular Medicine (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
SE REFIERE A UN ANTICUERPO MONOCLONAL QUE RECONOCE SULFATIDOS Y PROTEOGLICANOS SULFATADOS CUYA SECUENCIA DE LAS REGIONES DE LA COMPLEMENTARIEDAD DE LA REGION VARIABLE DE LA CADENA PESADA SON i) HCDR1: RYSVH; ii) HCDR2: MIWGGGSTDYNSALKS Y iii) HCDR3: SGVRRGRAQAWFAY; Y DE LA CADENA LIGERA SON i) LCDR1: KASQDVSTAVA; ii) LCDR2: SASYRYT Y iii) LCDR3: QQHYSTPWT. DONDE LA SECUENCIA DE LAS REGIONES CONSTANTES DEL ANTICUERPO SON IgG1 HUMANA PARA LA CADENA PESADA Y Ck HUMANA PARA LA CADENA LIGERA. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. DICHO ANTICUERPO ES UTIL EN EL TRATAMIENTO DE ENFERMEDADES CARDIOVASCULARES TAL COMO LESIONES ATEROSCLEROTICAS
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CU20090071A CU23736A1 (es) | 2009-05-04 | 2009-05-04 | Anticuerpos que reconocen sulfatidos y proteoglicanos sulfatados y su uso |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20100808A1 true PE20100808A1 (es) | 2011-01-07 |
Family
ID=42355373
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2010000230A PE20100808A1 (es) | 2009-05-04 | 2010-04-15 | Anticuerpos que reconocen sulfatidos y proteoglicanos sulfatados |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US8470322B2 (es) |
| EP (1) | EP2428521B1 (es) |
| JP (1) | JP5354823B2 (es) |
| KR (1) | KR101374263B1 (es) |
| CN (1) | CN102414222B (es) |
| AR (1) | AR076495A1 (es) |
| AU (1) | AU2010244859B2 (es) |
| BR (1) | BRPI1013991B1 (es) |
| CA (1) | CA2758994C (es) |
| CL (1) | CL2010000413A1 (es) |
| CU (1) | CU23736A1 (es) |
| ES (1) | ES2656849T3 (es) |
| MX (1) | MX2011011665A (es) |
| MY (1) | MY158954A (es) |
| PE (1) | PE20100808A1 (es) |
| RU (1) | RU2502744C2 (es) |
| SG (1) | SG175849A1 (es) |
| TW (1) | TWI424852B (es) |
| WO (1) | WO2010127642A1 (es) |
| ZA (1) | ZA201108832B (es) |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5770198A (en) | 1988-05-18 | 1998-06-23 | The Research Foundation Of The State Of New York | Platelet-specific chimeric 7E3 immunoglobulin |
| US5196324A (en) | 1989-12-15 | 1993-03-23 | Eli Lilly And Company | Monoclonal antibodies reactive with a human atheroma associated antigen |
| US20020018808A1 (en) | 1990-12-10 | 2002-02-14 | Alving Carl R. | Vaccines against sterols |
| US5541296A (en) | 1991-08-30 | 1996-07-30 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | Monocyte adhesion protein and monoclonal antibody thereto |
| US6471965B1 (en) | 1994-07-27 | 2002-10-29 | Bio-Virus Research Incorporated | Vaccine containing whole killed herpes viruses to prevent development of atherosclerotic plaque |
| JP4315257B2 (ja) * | 1995-11-13 | 2009-08-19 | 生化学工業株式会社 | 新規コンドロイチン硫酸プロテオグリカン、そのコア蛋白質、それをコードするｄｎａおよびそれに対する抗体 |
| CA2250428A1 (en) | 1996-05-01 | 1997-11-06 | T Cell Sciences, Inc. | Plasmid-based vaccine for treating atherosclerosis |
| CA2263316A1 (en) | 1996-08-14 | 1998-02-19 | Klara Berencsi | Methods and compositions for preventing or retarding the development of atherosclerotic lesions |
| US6183752B1 (en) | 1997-02-05 | 2001-02-06 | Pasteur Merieux Serums Et Vaccins | Restenosis/atherosclerosis diagnosis, prophylaxis and therapy |
| AU3817899A (en) | 1998-04-15 | 1999-11-01 | Inserm | Therapy of atherosclerosis |
| US6808713B1 (en) | 1998-12-28 | 2004-10-26 | Aventis Pasteur Limited | Chlamydia antigens and corresponding DNA fragments and uses thereof |
| US20030100508A1 (en) * | 1999-02-24 | 2003-05-29 | Maryline Simon | Carbohydrate epitope mimic compounds and uses thereof |
| ATE265860T1 (de) | 2000-03-03 | 2004-05-15 | Glaxosmithkline Biolog Sa | Impstoff zur behandlung von atherosclerosis |
| SE0000855D0 (sv) | 2000-03-15 | 2000-03-15 | Karolinska Innovations Ab | Antigenic composition useful as a vaccine against atherosclerosis |
| GB0121171D0 (en) | 2001-08-31 | 2001-10-24 | Glaxosmithkline Biolog Sa | Vaccine |
| US20030105003A1 (en) | 2001-04-05 | 2003-06-05 | Jan Nilsson | Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
| CU23007A1 (es) * | 2001-04-06 | 2004-12-17 | Ct De Inmunologia Molecular Ct De Inmunologia Mole | Combinaciones inmunoterapéuticas para el tratamiencombinaciones inmunoterapéuticas para el tratamiento de tumores que sobre-expresan gangliósidos to de tumores que sobre-expresan gangliósidos |
| SE0302312D0 (sv) | 2002-10-04 | 2003-08-27 | Forskarpatent I Syd Ab | Peptide-based passive immunization therapy for treatment of atherosclerosis |
| GB0305790D0 (en) | 2003-03-13 | 2003-04-16 | Glaxosmithkline Biolog Sa | Novel Composition |
| GB0305794D0 (en) | 2003-03-13 | 2003-04-16 | Glaxosmithkline Biolog Sa | Vaccine |
| GB0305793D0 (en) | 2003-03-13 | 2003-04-16 | Glaxosmithkline Biolog Sa | Vaccine |
| US20070122419A1 (en) | 2003-04-11 | 2007-05-31 | The Regents Of The University Of California | Methods and compositions for treating atherosclerosis |
| AR045563A1 (es) | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
| SE0302422D0 (sv) | 2003-09-11 | 2003-09-11 | Forskarpatent I Syd Ab | Peptide-based immunization therapy for treatment of atherosclerosis |
| SI1735349T1 (sl) | 2004-04-15 | 2010-12-31 | Athera Biotechnologies Ab | Postopek ocenitve tveganja ishemske kardiovaskularne bolezni z uporabo fosforilholinskih konjugatov |
| US20060276400A1 (en) | 2005-06-06 | 2006-12-07 | Hedy Adari | Modulation of cholesteryl ester transfer protein (CETP) activity |
| FR2906533B1 (fr) * | 2006-09-28 | 2013-02-22 | Pf Medicament | Procede de generation d'anticorps actifs contre un antigene de resistance,anticorps obtenus par ledit procede et leurs utilisations |
-
2009
- 2009-05-04 CU CU20090071A patent/CU23736A1/es active IP Right Grant
-
2010
- 2010-04-14 TW TW099111628A patent/TWI424852B/zh active
- 2010-04-15 PE PE2010000230A patent/PE20100808A1/es not_active Application Discontinuation
- 2010-04-26 CL CL2010000413A patent/CL2010000413A1/es unknown
- 2010-04-29 AR ARP100101450A patent/AR076495A1/es active IP Right Grant
- 2010-05-03 EP EP10721287.0A patent/EP2428521B1/en active Active
- 2010-05-03 RU RU2011149252/10A patent/RU2502744C2/ru active
- 2010-05-03 CN CN201080019730.6A patent/CN102414222B/zh active Active
- 2010-05-03 MY MYPI2011005199A patent/MY158954A/en unknown
- 2010-05-03 MX MX2011011665A patent/MX2011011665A/es active IP Right Grant
- 2010-05-03 ES ES10721287.0T patent/ES2656849T3/es active Active
- 2010-05-03 SG SG2011080298A patent/SG175849A1/en unknown
- 2010-05-03 JP JP2012508894A patent/JP5354823B2/ja active Active
- 2010-05-03 AU AU2010244859A patent/AU2010244859B2/en not_active Ceased
- 2010-05-03 WO PCT/CU2010/000002 patent/WO2010127642A1/es not_active Ceased
- 2010-05-03 BR BRPI1013991-5A patent/BRPI1013991B1/pt active IP Right Grant
- 2010-05-03 US US13/264,105 patent/US8470322B2/en active Active
- 2010-05-03 CA CA2758994A patent/CA2758994C/en active Active
- 2010-05-03 KR KR1020117024741A patent/KR101374263B1/ko active Active
-
2011
- 2011-12-01 ZA ZA2011/08832A patent/ZA201108832B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN102414222A (zh) | 2012-04-11 |
| US20120121605A1 (en) | 2012-05-17 |
| KR20120016055A (ko) | 2012-02-22 |
| EP2428521B1 (en) | 2018-01-03 |
| BRPI1013991A2 (pt) | 2016-04-05 |
| WO2010127642A9 (es) | 2011-03-24 |
| ES2656849T3 (es) | 2018-02-28 |
| CL2010000413A1 (es) | 2011-02-25 |
| JP2012526056A (ja) | 2012-10-25 |
| JP5354823B2 (ja) | 2013-11-27 |
| TW201103559A (en) | 2011-02-01 |
| RU2502744C2 (ru) | 2013-12-27 |
| US8470322B2 (en) | 2013-06-25 |
| MY158954A (en) | 2016-11-30 |
| CU23736A1 (es) | 2011-11-15 |
| ZA201108832B (en) | 2012-08-29 |
| BRPI1013991B1 (pt) | 2021-08-31 |
| WO2010127642A1 (es) | 2010-11-11 |
| HK1168362A1 (en) | 2012-12-28 |
| EP2428521A1 (en) | 2012-03-14 |
| CA2758994A1 (en) | 2010-11-11 |
| SG175849A1 (en) | 2011-12-29 |
| KR101374263B1 (ko) | 2014-03-13 |
| MX2011011665A (es) | 2012-06-01 |
| AU2010244859A1 (en) | 2011-12-08 |
| RU2011149252A (ru) | 2013-06-10 |
| TWI424852B (zh) | 2014-02-01 |
| CN102414222B (zh) | 2014-07-16 |
| CA2758994C (en) | 2015-07-21 |
| AU2010244859B2 (en) | 2014-05-29 |
| AR076495A1 (es) | 2011-06-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20170903A1 (es) | Conjugados de farmacos con anticuerpos anti-cdh6 | |
| PE20141147A1 (es) | Anticuerpos a pcsk9 y usos de los mismos | |
| PE20190630A1 (es) | Anticuerpos de anti-tim-3 | |
| PE20150159A1 (es) | Composiciones y metodos para anticuerpos que actuan sobre el factor p | |
| PE20140247A1 (es) | Anticuerpos anti-cd38 | |
| PE20141017A1 (es) | Anticuerpos del cea | |
| NZ603607A (en) | Cgrp antibodies | |
| PE20181326A1 (es) | Anticuerpos que se unen especificamente a pd-1 y sus usos | |
| PE20200011A1 (es) | ANTICUERPOS ANTI-PEPTIDO BETA AMILOIDE N3pGlu Y SUS USOS | |
| PE20210045A1 (es) | Anticuerpos agonistas contra pd-1 y usos de estos | |
| PE20091351A1 (es) | Anticuerpos humanizados especificos para el factor von willebrand | |
| PE20212088A1 (es) | Anticuerpos anti-tau y uso de los mismos | |
| PE20142243A1 (es) | Anticuerpos que se unen a ox40 y sus usos | |
| PE20141568A1 (es) | Anticuerpos humanizados que reconocen la alfa-sinucleina | |
| PE20141432A1 (es) | Anticuerpos neutralizantes de citomegalovirus humano | |
| PE20191045A1 (es) | Anticuerpos anti-il-33 y usos de los mismos | |
| PE20191408A1 (es) | Proteinas de union a antigeno st2 | |
| PE20131403A1 (es) | Anticuerpos anti-ox40 y metodos de uso de los mismos | |
| PE20110808A1 (es) | Anticuerpos contra el receptor 3 de tipo toll | |
| ES2687282T3 (es) | Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos | |
| PE20141166A1 (es) | Anticuerpos anti-angptl3 y usos de los mismos | |
| PE20130817A1 (es) | Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos | |
| PE20120553A1 (es) | Anticuerpos anti-fgfr3 | |
| NZ610294A (en) | Human antibodies to human tnf-like ligand 1a (tl1a) | |
| PE20130393A1 (es) | Anticuerpos con union de antigenos dependiente de ph |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |